Heart failure patients remain underserved, while conventional inotropes can cause arrhythmias, ischaemia, hypotension and increased mortality; AnaCardio is testing AC01 as an oral calcium-sensitizing therapy intended to improve cardiac contractility without those safety concerns. The latest €62.5 million Series B is intended to fund the approximately 400-patient Phase 2b GOAL-HF2 study and advance AC01 toward Phase 3 readiness by 2028, following reported Phase 1b/2a improvements in cardiac output and ejection fraction.